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Abstract 
 
Background: 
Nearly 20% of adult Americans used herbal therapies in 2007, but greater than two-thirds failed 
to report such use to their medical provider.  Significant patient harm may occur when herbal 
supplements are taken in conjunction with warfarin; however, patients and medical providers 
may not be aware of these interactions and this may place patients at risk for life-threatening 
bleeds or thrombotic complications. 
 
Methods: 
The authors determined the top 25 herbal and 25 nonherbal supplements used by Americans 
using sales data from 2008, and each product was reviewed for its potential to interact with 
warfarin.  Electronic searches were conducted using the Natural Medicines Comprehensive 
Database, AltMedDex (Micromedex) and Natural Standards databases.  Search terms included 
common herbal names, warfarin, and anticoagulants.  Databases were reviewed for herb-drug 
interactions with warfarin.  Supplements with a purported theoretical interaction only were 
excluded from the analysis.    
 
Results: 
Of the most commonly used herbal and nonherbal supplements used, more than half demonstrate 
a clinically significant drug interaction with warfarin therapy.   Specifically, 8 of 13 were found 
to potentiate a bleeding risk, and 5 of 13 were found to decrease the effectiveness of warfarin.  
Documented bleeding events have been linked to the use of some of these products (e.g. 
cranberry, garlic, ginkgo, and saw palmetto); whereas others have been found to demonstrate a 
clinically significant increase (e.g. glucosamine / chondroitin, essential fatty acids, multi-herb 
products, evening primrose oil) or decrease (e.g. coenzyme Q10, soy, melatonin, ginseng, St. 
John’s wort) in prothrombin time and required warfarin dose adjustments or vitamin K 
administration.     
 
Conclusions: 
Of the most commonly used herbal and nonherbal supplements, the majority impacted 
prothrombin times and 26% significantly impacted warfarin therapy safety or efficacy. The 
combined use of herbal-warfarin products has the potential to result in significant bleeding or 
thrombotic sequelae complicating the management of an already high-risk medication.  Medical 
providers must be proactive in asking about supplement use and then discussing the risks of 
herbal-warfarin interactions with their patients.   
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Review of Literature 
Warfarin 
Warfarin sodium, commonly known under the brand name Coumadin, is a popular 
anticoagulant drug.  It is the most widely prescribed oral anticoagulant in North America and has 
been proven effective in the prevention of thromboembolic events in patients with chronic atrial 
fibrillation, prosthetic heart valves, venous thromboembolism, and coronary artery disease (1).  
Coumarins or vitamin K antagonists (VKAs) have been the foundation of oral anticoagulant 
therapy for more than 50 years (2).   
Atrial Fibrillation 
Atrial fibrillation (AF) is a cardiac arrhythmia affecting an estimated in 2.2 million 
people in America and 4.5 million in the European Union (3).  In some cases, AF can cause chest 
pain or heart failure, especially when the heart rhythm is very rapid (4).  Frequently, people who 
have AF are asymptomatic.  However, even if asymptomatic, AF can increase the risk of stroke 
(4).  About 15 percent of patients with AF have experienced a stroke (5). 
Clinical risk factors for AF include advanced age, diabetes, hypertension, congestive 
heart failure, rheumatic and nonrheumatic valve disease, and myocardial infarction (6).  Three 
to five percent of people older than 65 years have atrial fibrillation (5).  To reduce stroke risk in 
patients with AF, anticoagulant and antiplatelet medications are used to thin the blood reducing 
risk for emboli (5).  Warfarin is the anticoagulant most frequently used for this purpose, and 
aspirin is the antiplatelet drug most often used (5).  Long-term use of warfarin in patients with 
AF and other stroke risk factors can reduce stroke by 68 percent (5). 
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Use of HDS in the US 
In 1994, the Dietary Supplement Health & Education Act (DSHEA) was passed that 
defines a supplement as: a product other than tobacco, is intended to supplement the diet, 
contains one or more dietary ingredients, intended to be taken by mouth, and labeled as being a 
dietary supplement (7).  In 2004, dietary supplement sales exceeded $20 billion (8).  According 
to the National Center for Complementary and Alternative Medicine (NCCAM), “a national 
survey conducted in 2007 found that 17.7 percent of American adults had used "natural 
products" (i.e., dietary supplements other than vitamins and minerals) in the past 12 months (9).  
The most popular products used by adults for health reasons in the past 30 days were fish 
oil/omega 3/DHA (37.4%), glucosamine (19.9%), echinacea (19.8%), flaxseed oil or pills 
(15.9%), and ginseng (14.1%)” as seen in figure 1 (10).   
 
Figure 1: Frequencies and age-adjusted percentages of adults ≥18 yrs old who used nonvitamin, nonmineral, 
natural products for health reasons in the past 30 days. 
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Use of VKAs 
In clinical practice, the use of VKAs is complicated.  First, they have a limited 
therapeutic window.  Second, they exhibit substantial variability in dose response among 
subjects. Third, they are susceptible to interactions with drugs and diet.  Fourth, they have 
laboratory control that can be difficult to standardize.  Lastly, there are difficulties in dosing as a 
consequence of patient nonadherence and miscommunication between the physician and patient 
(2).  Warfarin use is somewhat restricted by a justifiable fear of bleeding as well as drug and food 
interactions that are frequently cited as causes of adverse events with warfarin.  Noting this 
challenging situation in the utilization of warfarin, safety must be carefully practiced while 
taking it.   
Mechanism of Warfarin 
The effects of warfarin occur due to interference with the cyclic interconversion of 
vitamin K and its 2,3 epoxide (vitamin K epoxide).  Vitamin K is a cofactor for the carboxylation 
of glutamate residues to -carboxyglutamates (Gla) on the N-terminal regions of vitamin K-
dependent proteins (11).  These proteins include coagulation factors II, VII, IX, and X, and 
require vitamin K for -carboxylation for biological activity.  By inhibiting the vitamin K 
conversion cycle, warfarin stimulates hepatic production of partially decarboxylated proteins 
with decreased coagulant activity (11). 
Carboxylation supports binding of the vitamin K-dependent coagulation factors to 
phospholipid surfaces, thus increasing blood coagulation (11).  In order for -carboxylation to 
work effectively, the reduced form of vitamin K (vitamin KH2) is required.  Coumarins block the 
formation of vitamin KH2 by inhibiting the enzyme vitamin K epoxide reductase, thereby 
restricting the -carboxylation of the vitamin K-dependent coagulant proteins (11).  The vitamin 
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K antagonists also inhibit carboxylation of the regulatory anticoagulant proteins C and S.  Low 
doses of vitamin K1 (phytonadione) are capable of aiding in overcoming the anticoagulant effect 
of coumarins because vitamin K1 bypasses vitamin K epoxide reductase (11).  Subjects treated 
with large doses of vitamin K1 (usually greater than five mg) can be unaffected by warfarin for 
up to a week because vitamin K1 accumulating in the liver is available to bypass vitamin K 
epoxide reductase (11). Figure 2 depicts warfarin interaction in the vitamin K cycle (12). 
  
Figure 2: Warfarin Interaction in the Vitamin K Cycle 
 
Factors Influencing Warfarin’s Effects 
The anticoagulant response to warfarin is affected by pharmacokinetic factors, including 
drug and herbal/nonherbal supplement interactions that affect its absorption or metabolic 
clearance, genetic factors such as hereditary resistance to warfarin, and food interactions such as 
dietary vitamin K intake (11).  Warfarin requires monitoring and frequent dose adjustment to 
maintain the desired therapeutic action and minimize adverse bleeding events.  A thrombosis is a 
result of underanticoagulation, which can be fatal.  A hemorrhage is a result of over-
anticoagulation, which can also be life-threatening.  Length of treatment varies, from 6 weeks to 
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6 months for venous thrombosis, to life-long treatment for cardiac indications or repeated 
thrombosis (13). 
Patients taking oral anticoagulant drugs, such as warfarin, must regulate their 
international normalized ratio (INR) measured routinely with appropriate anticoagulant dose 
adjustment.  Some patients are particularly sensitive to oral anticoagulants and, in such 
individuals, small increases in dose, or introduction or discontinuation of interacting medicines, 
herbal preparations and certain foods can cause significant changes in the anticoagulant effect 
(13).  Polypharmacy is not uncommon, which complicates the efficacy of warfarin.  Patients 
taking warfarin should be aware of the risks of taking other prescribed or purchased medicines, 
herbal products and specific foods without first discussing it with their physician. 
Dietary Interactions with Warfarin 
As previously stated, warfarin use is subject to dangerous interactions with other 
medications as well as some food products.  Due to the actions of warfarin interfering with the 
vitamin K conversion cycle, dietary vitamin K intake must remain consistent on a daily basis to 
reduce the risk of hemorrhage or thrombosis.  Persons on long-term warfarin therapy are 
vulnerable to fluctuating levels of dietary vitamin K, which is obtained predominantly from 
phylloquinones found in plant foods (11).   
Phylloquinones inhibit the anticoagulant effect of warfarin because they are reduced to 
vitamin KH2 through the warfarin-insensitive pathway (11).
  Significant fluctuations in vitamin K 
intake occur in both healthy and sick individuals. Increased intake of dietary vitamin K sufficient 
to lessen the anticoagulant effect of warfarin occurs in patients consuming green vegetables or 
vitamin K-containing supplements while following weight-reduction diets as well as in patients 
supplementing with intravenous vitamin K (11).  Reduced dietary vitamin K intake has the 
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potential to affect warfarin efficacy in sick patients treated with antibiotics and intravenous fluids 
without vitamin K supplementation and in circumstances of fat malabsorption (11). 
Medicinal Interactions with Warfarin 
Warfarin also interacts with some common drugs such as aspirin, nonsteroidal 
antiinflammatory drugs (NSAIDs), and penicillins in high doses (11).  These drugs inhibit 
platelet function and thus increase the risk of warfarin-associated bleeding.  Of these, aspirin is 
the most critical because of its universal use and drawn out effect.  Aspirin and nonsteroidal 
antiinflammatory drugs can also increase the risk of upper gastrointestinal bleeding as a result of 
them producing gastric erosions (11).  The risk of clinically significant bleeding is amplified 
when elevated amounts of aspirin are taken throughout high-intensity warfarin therapy (11). 
Herbal and Nonherbal Dietary Supplement Interactions with Warfarin 
Warfarin has been documented to interact with herbal and nonherbal dietary supplements 
(HDS) (11).  However, little is known about the great extent to which some of the most 
commonly used HDS may impact warfarin safety and efficacy.  Although herbal remedies are 
perceived as being natural and therefore safe, many have adverse effects that can sometimes 
produce life-threatening consequences. 
It is important to determine the degree to which HDS can interfere with warfarin because 
of the rapidly growing dietary supplement market and consumer demand in the United States.  
According to the research completed through this thesis, the top five products in Figure 1 (fish 
oil, flaxseed oil, glucosamine, echinacea, and ginseng) were shown to have an interaction with 
warfarin. Also, as documented in the manuscript portion of this thesis, garlic (37-45), ginkgo 
(49, 52-56) and St. John’s wort (80-84) should be avoided while taking warfarin.  Because of the 
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high risk of adverse effects while concurrently taking these common HDS and warfarin, a brief 
review of each HDS will follow. 
Fish Oil and Flaxseed Oil 
Fish oil and flaxseed oil both had minor interactions, mainly with platelets (35-36).  
Many people consume fish and flax seed oils because of the purported health benefits of the 
omega-3 fatty acids they contain. Omega-3 fatty acids have been thought to reduce the risk for 
cardiovascular disease and some cancers, as well as improve brain health.  Some research has 
shown that the omega-3 component of fish oils may suppress thromboxane A2 synthesis.  This 
may intensify the effects of warfarin, thus increasing the chances of bleeding.  Conflicting 
research has suggested that fish oil does not have an additive effect with aspirin.  Data does 
suggest that 3-6g/day does not affect INR (35-36).   
Ginseng 
The source of the ginseng root and its method of extraction can result in a wide array of 
ginseng products.  Ginseng is touted as an immune system stimulant that increases vigor, sexual 
potency, and longevity, and for use as an antidiabetes agent (14).  It is also used as medicine in 
Chinese culture for congestive heart failure (CHF), myocardial infarction, and angina pectoris 
(14).  Ginseng use should be avoided while taking warfarin (76-78).  Ginseng may inhibit 
platelet aggregation consequently decreasing the effects of warfarin.  A recent study inspecting 
the effect of 3 weeks of American ginseng on the effect of warfarin in healthy volunteers found a 
statistically significant but quantitatively small decrease in INR of 0.19, as well as a decrease in 
warfarin plasma area under the curve (AUC) (15).  These results imply that this specific ginseng 
preparation may produce a minor reduction in the efficacy of warfarin, perhaps by way of 
accelerated clearance. 
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Glucosamine   
Glucosamine is recommended to be used with caution while taking warfarin although the 
exact mechanism of the interaction is unknown (2-4).  Glucosamine is a chemical component of 
heparin, a widely used injectable anticoagulant (16).  It is possible that the combining of warfarin 
with higher-dose glucosamine and chondroitin might have had an additive pharmacodynamic 
effect on coagulation (16).  At the usual dosages of glucosamine (1500 mg) and chondroitin 
(1200 mg) used on a daily basis, these supplements alone or in combination do not appear to 
cause a clinically significant interaction with warfarin (16).  Nevertheless, it is advised to 
monitor for INR changes in patients taking warfarin and beginning a supplement or drug that has 
not been thoroughly investigated for its effect on warfarin. 
Echinacea 
Echinacea is commonly thought to stimulate the immune system and therefore prevent 
infections.  It has been shown to have minor interactions with warfarin.  Flavonoids from 
echinacea may inhibit or induce cytochrome P450 enzymes, depending on their structure and 
assay conditions (14).  A minor impact of CYP function was established through in vivo 
assessment of botanical supplementation on human cytochrome P450 phenotypes: citrus 
aurantium, echincea purpurea, milk thistle, and saw palmetto. 
Garlic 
Garlic is often used by patients for remedy of infectious conditions because of its 
presumed antimicrobial and immune-boosting activity.  Garlic has been considered to have 
cholesterol-lowering and other antiatherosclerotic and antihypertensive properties and is used in 
the prevention of cardiovascular disease (14).  It has been shown to increase fibrinolytic activity, 
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and may inhibit platelet aggregation by reducing thromboxane B2 thereby, increasing risk for 
bleeding.   
Garlic’s active component, ajoene inhibits collagen-induced platelet aggregation; thus, 
patients with cardiovascular disease often use garlic for its antiplatelet and fibrinolytic effects 
(14).  Nevertheless, the risk of bleeding in patients using warfarin increases, so its concomitant 
use should be avoided.  It is worthy to note that not all garlic products contain the constituents 
that possess “antiplatelet properties”.  It has been advised that garlic supplements be 
discontinued ten days prior to surgery to prevent excessive bleeding.  Ingestion of normal 
amounts of dietary garlic should not affect bleeding times (37-45). 
Ginkgo 
Ginkgo is a popular HDS and is one of the bestselling herbal remedies in the United 
States for cognitive impairment (14).  Ginkgo biloba beginnings date back centuries to the 
Permian period, making it one of the world’s oldest living tree species (14).  The main 
implications for ginkgo use are peripheral vascular disease such as intermittent claudication and, 
more chiefly, "cerebral insufficiency" (17).  It has been documented to increase the risk of 
bleeding while taking warfarin.  This is thought probable by inhibition of cytochrome P450 2C9 
by ginkgo.  Also, ginkgo is thought to displace platelet activating factor (PAF), inhibiting PAF-
induced platelet aggregation. 
St. John’s Wort 
St. John’s wort is frequently used to treat depression, anxiety, sleep disorders, the 
common cold, herpes, and the human immunodeficiency virus (HIV) (14).  It acts as a hepatic 
cytochrome P450 enzyme inducer (CYP2C9, CYP1A, CYP3A4).  Simultaneous use of St. 
John’s wort with warfarin reduces prothrombin time, which may produce subtherapeutic 
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anticoagulation and increase the risk of thromboembolism (14).  Patients with a history of stroke, 
thrombosis, atrial fibrillation, or prosthetic cardiac valves should avoid the use of St. John’s wort 
while taking warfarin (14). 
Conclusion 
From this evidence alone, there are major risks when using HDS and warfarin 
concomitantly.  Steps must be taken to bridge the communication gap that exists between 
physicians and patients with regard to supplement use.  To ensure that patients are taking 
warfarin safely, physicians must be aware of the risks HDS pose with concomitant use of 
warfarin. Physicians must be proactive in asking their patients about such use and discussing the 
risks involved to aid in preventing serious complications with an already high risk medication. 
 
15 
 
References 
 
1. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. 
Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 
2005;165:1095-1106. 
 
2. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management 
of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and 
Thrombolytic Therapy. Chest. 2004;126(3):2045-2335. 
 
3. Fuster V, Ryden LE, Cannon DS, Crijns Hj, Curtis AB, Ellenbogen KA, Halperin JL, 
Heuzey J-YL, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL,Wann S. 
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial 
Fibrillation. Circulation. 2006;114:e257-e354. 
 
4. National Heart, Lung and Blood Institute. Atrial Fibrillation. Available at: 
http://www.nhlbi.nih.gov/health/dci/Diseases/af/af_what.html. Accessed April 15, 2010. 
 
5. American Heart Association. Atrial Fibrillation. Available at: 
http://www.americanheart.org/presenter.jhtml?identifier=4451. Accessed April 15, 2010. 
 
6. Benjamin EJ, Wolf PA,  D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of 
Atrial Fibrillation on the Risk of Death: The Framingham Heart Study. Circulation. 
1998;98(10):946-952. 
 
7. Saldanha LG. Opening Comments: What are Dietary Supplements? Introduction. 
American Dietetic Association's Food & Nutrition Conference & Expo (FNCE). 
2005;Session 250. 
 
8. Picciano MF. Who Is Using Dietary Supplements and What are They Using? American 
Dietetic Association's Food & Nutrition Conference & Expo (FNCE). 2005;Session 250. 
 
9. National Center for Complementary and Alternative Medicine. Get the Facts: Using 
Dietary Supplements Wisely. Available at: 
http://nccam.nih.gov/health/supplements/wiseuse.htm. Accessed March 30, 2010. 
 
10. Barnes PM, Bloom B, Nahin R. Complementary and Alternative Medicine Use Among 
Adults and Children: United States, 2007. National Health Statistics Reports. 2008:12;1-
24. 
 
11. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College 
of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol. 2003;41:1633-
1652. 
 
12. Linus Pauling Institute of Medicine. The Vitamin K Cycle. Available at: 
http://lpi.oregonstate.edu/infocenter/vitamins/vitaminK/kcycle.html. Accessed April 21, 
2010. 
16 
 
 
13. Baglin TP, Cousins D, Keeling DM, Perry DJ, Watson HG. Recommendations from the 
British Committee for Standards in Haematology and National Patient Safety Agency. Br 
J Haematol. 2006;136(1):26-29. 
 
 
14. Greenblatt DJ, von Moltke LL. Interaction of Warfarin with Drugs, Natural Substances, 
and Foods. J Clin Pharmacol. 2005;45:127-132. 
 
15. Tachjian A, Maria V, Jahangir A. Use of Herbal Products and Potential Interactions in 
Patients with Cardiovascular Diseases. J Am Coll Cardiol. 2010;55:515-525. 
 
16. Scott GN. Interaction of Warfarin with Glucosamine—Chondroitin. Am J Health-Syst 
Pharm. 2004;61:1186. 
 
17. Kleijnen J, Knipschild P. Ginkgo Biloba. Lancet. 1992;340(1136):4p. 
17 
 
Manuscript 
 
Significant interactions with the most commonly used herbal and nonherbal supplements 
impact warfarin safety and efficacy 
 
 Jennifer Strohecker1, Megan B. Smith2, Nedra Christensen2, Brittany Sagers2,  John D. Day3, J. 
Peter Weiss3, Brian G. Crandall3,  Jeffrey S. Osborn3, Jeffrey L. Anderson3, Brent Muhlestein3, 
Donald L. Lappe3, T. Jared Bunch2,3 
 
 
1 Intermoumtain Medical Center, Murray, Utah 
2 Department of Nutrition and Food Sciences, Utah State University, Logan, Utah 
3 Department of Cardiology, Intermountain Medical Center, Murray, Utah 
Address for correspondence:        T. Jared Bunch, M.D. 
Intermountain Heart Rhythm Specialists, 
Intermountain Medical Center 
Eccles Outpatient Care Center 
5169 Cottonwood St, Suite 510 
Murray, Utah, 84107 
Fax: 801-507-3584 
E-mail: Thomas.bunch@imail.org 
  
18 
 
Introduction: 
            For centuries, botanicals and their derivatives have been utilized for prevention and 
treatment of disease.  Indeed, even today, due to extensive availability and widespread 
acceptance, herbal and dietary supplement (HDS) use has become commonplace.  One out of 
five American’s reports using at least one HDS in the last twelve months, a trend that has 
continued to gain momentum over the last decade (1).   Growing concern for patient safety has 
driven international and national groups in efforts towards regulation of the herbal supplement 
industry, but with limited success.  In the present day era of patient guided research, selection 
and self-treatment with supplements, it is imperative that medical providers be proactive in 
inquiry about HDS use and provide relevant guidance in efforts to minimize potential adverse 
events.  When combined with prescription drugs, herbal-drug interactions are of great concern 
because they may lead to unexpected, serious patient harm. 
The supplement industry is the fastest growing share of the US pharmaceutical industry, 
with annual earnings approaching 24 billion dollars in 2007 (2).  Today, greater than 1500 
products claiming “functional support” of the bodies various organ systems line the shelves of 
pharmacies and health food stores, easily accessible to an often uneducated consumer.  
Ironically, HDS are not considered “drugs” by the Food and Drug Administration (FDA), and are 
therefore free from the safety and regulatory standards set in place by the FDA for other over the 
counter and prescription products.  In 1994, the Dietary Supplement Health and Education Act 
(DSHEA) was passed and outlines the US regulations set in place for herbal and nonherbal 
supplements: the manufacturer is to ensure that the product is safe and labeling must include 
product ingredients (3).  As a food source the preparation, packing, and holding of HDS are 
governed by the FDA’s ‘Good Manufacturing Practices’ (4).  In June of 2007, the FDA 
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established regulations to require current ‘Good Manufacturing Practices” for dietary 
supplements that require dietary supplement manufacturers to evaluate the identity, purity, 
strength, and composition of their dietary supplements (5).  Although these measures may help, 
the quandary with HDS continues to be, that the pharmacologic effects of these products are 
undefined, unpredictable, and potentially unsafe, yet the well-intended consumer has little 
knowledge of this.   This can present the greatest risk to patients with multiple medical co-
morbidities, fragile end organ function, and those on complicated drug regimens.  In 2002, the 
World Health Organization launched a global strategy with end goals of promoting consumer 
safety through industry regulation and standardization (6).  Clearly, the unregulated use of HDS 
is not just a national, but an international concern. 
The introduction of warfarin sodium in 1954 revolutionized the prophylaxis and 
treatment of thromboembolic disorders, and remains the gold standard oral anticoagulant.  More 
than 22 million prescriptions for warfarin were filled in 2008, and enormous health care 
resources are dedicated to its management.  In spite of efforts to achieve tight control of the 
international normalized ratio (INR), warfarin accounts for more emergency room visits than any 
other drug excluding insulin.  In 2009, the Joint Commission of Healthcare Accreditation made 
the appropriate use of warfarin a National Patient Safety Goal (7).  As part of this effort, it is 
crucial to understand the influence that HDS use may have on INR variability when taken 
concomitantly with warfarin.  Such an understanding must be constantly reappraised as the kinds 
of HDS used varies as well as their relative frequency and quantify of use. 
Methods: 
              The authors determined the top 20 herbal and 20 nonherbal supplements used by 
Americans using sales data from 2008 and each product was reviewed for its potential to interact 
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with warfarin (8).  Electronic searches were conducted using the Natural Medicines 
Comprehensive Database, AltMedDex (Micromedex) and Natural Standard databases.  Search 
terms included common herbal names, warfarin, and anticoagulants, and drug-drug interactions.  
Databases were reviewed for herb-drug interactions with warfarin.  Databases were searched for 
relevant case reports and any clinical trials which documented an herbal/supplement – drug 
interaction with reported changes in INR, bleed risks, or thromboembolic events.   Collected data 
was limited to English only reports and those with a documented human interaction. 
Supplements with a purported theoretical interaction only were excluded from the analysis.    
Results: 
            Of the 40 most commonly used herbal and nonherbal supplements, more than half 
demonstrate an indirect or direct drug interaction with warfarin therapy.   Of the top 10 most 
commonly used supplements, 80% have been reported to interact with warfarin therapy.  Overall, 
14 of 40 were associated with a clinically significant change in INR.  Specifically, 9 of 14 were 
found to potentiate a bleeding risk, and 5 of 14 were found to decrease the effectiveness of 
warfarin.  Documented bleeding events have been linked to the use of some of these products 
(e.g. cranberry, garlic, ginkgo, and saw palmetto); whereas others have been found to 
demonstrate a clinically significant increase (e.g. glucosamine / chondroitin, essential fatty acids, 
multi-herb products, evening primrose oil) or decrease (e.g. coenzyme Q10, soy, melatonin, 
ginseng, St. Johns’s wort) in prothrombin time thus necessitate warfarin dose adjustments or 
vitamin K administration.     
Discussion: 
           The HDS industry has experienced enormous growth with extensive consumer acceptance 
and trust.  A survey of 100 patients with CV disease on warfarin showed that many patients do 
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not view HDS as drugs, and most do not consult with their pharmacist/physician before taking a 
HDS (9).  More than 2/3 of patients who use HDS fail to communicate use to their 
physicians/pharmacists, and physicians often fail to ask patients about HDS consumption as well 
(5, 9).  The reasons for the communication gap are many: patients believe that health care 
professionals lack knowledge of or acceptance for HDS, patients perceive HDS as "natural" and 
do not relate their use to drug interaction (9), and medical providers may fail to ask about HDS 
use due to a lack of knowledge, confidence, or comfort with the subject matter (10).  Addressing 
these issues will be paramount as clinicians seek to bridge this gap in order to improve safety 
outcomes, particularly in high-risk patient groups. 
A survey of the literature shows that anticoagulant/antiplatelet therapies are among the 
drug classes most likely to interact with HDS (11).  Of the 40 most commonly used HDS, more 
than half demonstrated a clinically significant change in INR values, and the majority were 
associated with a bleeding event or thromboembolic complication.  While most of these reports 
are cited as individual case reports, the true level (degree/risk) of harm for warfarin-treated 
patients may actually be greater than is documented.  Pharmacokinetic properties and toxicity 
parameters of individual herbs are not well studied, and drug-drug, drug-disease interactions are 
largely unknown. Additionally, a vast number of supplements are not marketed as “single-entity” 
products, but rather a potpourri of dozens or hundreds of individual ingredients.  The new FDA 
regulation should impact quality of supplements.   Unfortunately, companies have to be 
compliant to the new regulation by supplement June 2008, 2009, or 2010, depending on the 
number of personnel employed at the company.  This will continue to impact the consistency of 
HDS in the marketplace.  Without prior study it is completely unclear if the enhanced quality 
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which may provide relatively higher or lower HDS concentrations with favorability or 
unfavorability impact the many drug-HDS interactions.   
Development, implementation, and adherence to a comprehensive management program 
that outlines standards of care have been shown to improve safety outcomes in anticoagulated 
patients. As such, inquiry and recommendation about herbal supplement use is an essential part 
of such a program.  Important aspects to incorporate may be the following:  proactive inquiry 
about herbal or supplement use separately from prescription or over the counter drug use; 
documentation of use in the medical record; active education of known risks/interactions 
between the specified herbal product and warfarin; and more frequent INR monitoring if 
necessary.   Other valuable education points for patients who use HDS may be:  encourage 
dialogue before use with physician/pharmacist; take the product consistently to achieve a more 
predictable effect on INR; to purchase the same brand of product to minimize constituent 
variability; follow up with routine testing as instructed; bring the HDS with them to all scheduled 
appointments; report any adverse events to their medical provider immediately.  Additionally, 
encourage selection of supplements that are verified by the United States Pharmacopeia (USP).  
Likewise, physicians and other medical providers must acknowledge a “communication 
gap” exists with their patients and make efforts to minimize this barrier.  Self-education is 
critical, so that a knowledgeable exchange about the supplement industry, including DHSEA and 
rationale for safety risks, can be undertaken with patients.  Physicians must recognize that HDS 
use is common and underreported, and therefore must be proactive and specific in patient 
interview.  It is essential to be forthright with regard to the risks/benefits of using supplements, 
so that the patient can make an informed and educated decision.  Likewise, it is imperative that 
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the physician be familiar with on-line herbal databases, such as AltMedDex (Micromedex), and 
utilizes them to search for herbal information, such as herbal-warfarin interactions.   
Steps must be taken to bridge the communication gap that exists between physicians and 
patients with regard to supplement use.  While warfarin remains the gold standard anticoagulant 
drug therapy for long-term management of patients at risk for thromboembolism, its safe use can 
be compromised by many factors, including HDS consumption.  Our data shows that of the most 
commonly used HDS, warfarin-related drug interactions are very common and have been 
associated with bleeding.  This risk is greatest in the 10 most commonly used herbal 
supplements, where 8 of 10 have demonstrated an HDS-warfarin interaction.  Our research 
highlights/emphasizes the widespread risk that warfarin-treated patients are exposed to when 
self-medicating with HDS.  It is imperative that action be taken to address communication-
related barriers with regard to HDS use, and should include the steps outlined above.  As 
hospitals seek to achieve compliance with the Joint Commission’s 2009 National Patient Safety 
Goals of medication reconciliation and appropriate anticoagulant management, this creates a 
perfect opportunity/forum for HDS-focused education.  Future research should be aimed at 
“bridging the gap” through the development and implementation of both physician-focused and 
patient-focused educational tools. 
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                                    Warfarin/HDS Interaction Table 
 
 
Supplement Recommendation 
for Management 
Warfarin 
Interaction 
Platelet 
Interaction 
Mechanism Patient Information 
CAM therapies that may increase the risk of bleeding 
Chondroitin 
sulfate (2-4) 
 
! +  Chondroitin is a small 
component of a 
heparinoid and might 
have weak anticoagulant 
activity 
 
Cod liver oil- 
Essential Fatty 
Acids (5-9) 
 
Q   Cod liver oil contains 
omega-3 fatty acids, 
which may interfere 
with the ?????  
 
Cranberry (10-
22) 
 
! +  Unknown mechanism: 
One proposed 
mechanism is that 
flavanoids in cranberry 
may interfere with the 
P450 2C9 metabolism of 
warfarin, thus 
prolonging its effects.  
Another hypothesis is 
that cranberry may 
increase the sensitivity 
of clotting factors to the 
effects of warfarin 
-Avoid drinking in large  
quantities  
-Have INR checked more  
frequently with chronic  
consumption 
 
Evening 
primrose oil (31) 
 
!  + Primrose oil contains 
gamma-linolenic acid 
which has been show to 
inhibit thromboxane B2 
production and increase 
prostacyclin production  
 
Fish oil- 
Essential Fatty 
Acids (35,36) 
 
Q  + Some research shows 
that the omega-3 
component of fish oil 
may suppress 
thromboxane A2 
synthesis.  Conflicting 
research suggests that 
fish oil does not have an 
additive effect with 
aspirin 
Data does suggest that 3-6g/day 
does not affect INR 
Garlic (37-45) 
 
∅  + Garlic has been shown 
to increase fibrinolytic 
-Not all garlic products contain  
the constituents that possess  
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Supplement Recommendation 
for Management 
Warfarin 
Interaction 
Platelet 
Interaction 
Mechanism Patient Information 
activity, and may inhibit 
platelet aggregation by 
reducing thromboxane 
B2 
“antiplatelet properties” 
-Garlic supplements should be  
stopped 10 days prior to surgery 
-Ingestion of normal amounts of 
dietary garlic should not affect  
bleeding times 
Ginger (34,46-
51) 
 
Q  + Mixed results in studies: 
one suggests a 
significant inhibition of 
platelet aggregation, 
where two others 
showed no affect on 
platelet function 
-Caution with intake exceeding  
4 grams of dried or 15 grams of  
raw ginger daily 
Ginkgo biloba 
(49, 52-56) 
 
∅ + + Probable cytochrome 
P450 2C9 inhibition by 
ginkgo. Also, ginkgo is 
thought to displace 
platelet activating factor 
(PAF), inhibiting PAF-
induced platelet 
aggregation 
 
Glucosamine (2-
4) 
 
!  + May have antiplatelet 
activity 
 
Melatonin (62) 
 
!   Unknown mechanism  
Saw palmetto 
(63, 64) 
 
!  + Saw palmetto may 
inhibiti cyclooxygenase, 
leading to increased risk 
of bleed 
 
CAM therapies 
that may 
decrease the 
effects of 
warfarin 
 
Coenzyme Q10 (72-74) 
 
Ginseng 
(American) 
(76-78) 
 
∅  + May inhibit platelet 
aggregation 
 
Ginseng ∅  + May inhibit platelet  
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Supplement Recommendation 
for Management 
Warfarin 
Interaction 
Platelet 
Interaction 
Mechanism Patient Information 
(Panax) (76-78) aggregation 
Soy (79) 
 
Q +  Soy isoflavones may 
alter warfarin drug 
absorption, metabolism 
or biliary excretion.  
They may also have 
antiplatelet effect 
 
St. John’s wort 
(80-84) 
 
∅ +  St. John’s wort is a 
cytochrome P450 
enzyme inducer 
(CYP2C9, CYP1A2, 
CYP3A4)  
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